ReviewNeuro-oncology advances

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis.

Iyad Alnahhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.